BLBX - BioMarin Pharmaceutical Aclaris Therapeutics Esperion Therapeutics among premarket losers' pack

2023-03-06 08:17:23 ET

• Aclaris Therapeutics ( ACRS ) -38% after preliminary topline data from 12-week Phase 2a study did not meet primary or secondary efficacy endpoints in hidradenitis suppurativa .
• Esperion Therapeutics ( ESPR ) -27% amid Nexletol data showing reduced risk of heart events .
• Adaptimmune Therapeutics ( ADAP ) -23% after strategic combination with TCR² Therapeutics; tops Q4 consensus .
• Embark Technology ( EMBK ) -16% .
• Etao International ( ETAO ) -12% .
• Cardio Diagnostics ( CDIO ) -11% .
• Asset Entities ( ASST ) -10% .
• OncoSec Medical ( ONCS ) -10% .
• Performance Shipping ( PSHG ) -7% .
• Silvergate Capital ( SI ) -7% after Silvergate Capital cut to Underperform at Wedbush on potential for liquidation .
• Blackboxstocks ( BLBX ) -7% .
• Altamira Therapeutics ( CYTO ) -6% .
• BioMarin Pharmaceutical ( BMRN ) -6% .
• Bullfrog AI ( BFRG ) -5% .

For further details see: